Giuseppe
Emeritus
Quantifying benefits and risks of vaccinating Australian children aged six months to four years with trivalent inactivated seasonal influenza vaccine in 2010 (abstract)
[Source: Eurosurveillance.org, full text: <cite cite="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19661">Eurosurveillance - View Article</cite>. Abstract, edited.]
Eurosurveillance, Volume 15, Issue 37, 16 September 2010
Rapid communications
Quantifying benefits and risks of vaccinating Australian children aged six months to four years with trivalent inactivated seasonal influenza vaccine in 2010
H Kelly 1, D Carcione 2, G Dowse 2, P Effler 2
1. Victorian Infectious Diseases Reference Laboratory, Melbourne, Australia
2. Communicable Disease Control Directorate, Department of Health Western Australia, Perth, Australia
Citation style for this article: Kelly H, Carcione D, Dowse G, Effler P. Quantifying benefits and risks of vaccinating Australian children aged six months to four years with trivalent inactivated seasonal influenza vaccine in 2010. Euro Surveill. 2010;15(37)
ii=19661. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19661
Date of submission: 12 August 2010
Australian and New Zealand health authorities identified seasonal trivalent inactivated influenza vaccines manufactured by CSL Biotherapies as the probable cause of increased febrile convulsions in children under five within 24 hours of vaccination and recommended against their use in this age group. We quantified the benefit-risk profile of the CSL vaccines using the number needed to vaccinate and suggest they might have caused two to three hospital admissions due to febrile convulsions for every hospital admission due to influenza prevented.
-
-----
[Source: Eurosurveillance.org, full text: <cite cite="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19661">Eurosurveillance - View Article</cite>. Abstract, edited.]
Eurosurveillance, Volume 15, Issue 37, 16 September 2010
Rapid communications
Quantifying benefits and risks of vaccinating Australian children aged six months to four years with trivalent inactivated seasonal influenza vaccine in 2010
H Kelly 1, D Carcione 2, G Dowse 2, P Effler 2
1. Victorian Infectious Diseases Reference Laboratory, Melbourne, Australia
2. Communicable Disease Control Directorate, Department of Health Western Australia, Perth, Australia
Citation style for this article: Kelly H, Carcione D, Dowse G, Effler P. Quantifying benefits and risks of vaccinating Australian children aged six months to four years with trivalent inactivated seasonal influenza vaccine in 2010. Euro Surveill. 2010;15(37)
ii=19661. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19661Date of submission: 12 August 2010
Australian and New Zealand health authorities identified seasonal trivalent inactivated influenza vaccines manufactured by CSL Biotherapies as the probable cause of increased febrile convulsions in children under five within 24 hours of vaccination and recommended against their use in this age group. We quantified the benefit-risk profile of the CSL vaccines using the number needed to vaccinate and suggest they might have caused two to three hospital admissions due to febrile convulsions for every hospital admission due to influenza prevented.
-
-----